Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 20, 2024 - Issue 6
Submit an article Journal homepage
336
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Genetic polymorphisms of drug-metabolizing enzymes in older and newer anti-seizure medications

Gianluca D’Onofrioa Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, ItalyView further author information
,
Andrea Santangeloa Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy;b Pediatric Neurology, Pediatric Department, AOUP Santa Chiara Hospital, Pisa, ItalyView further author information
,
Antonella Rivaa Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, ItalyView further author information
&
Pasquale Strianoa Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy;c Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto “Giannina Gaslini”, Genoa, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6065-1476View further author information
ORCID Icon
Pages 407-410 | Received 18 Apr 2024, Accepted 28 May 2024, Published online: 31 May 2024

References

  • Riva A, Roberti R, D’Onofrio G, et al. A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy. Epilepsia Open. 2023 Sep;8(3):1142–1150. doi: 10.1002/epi4.12717
  • Saruwatari J, Ishitsu T, Nakagawa K. Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy. Pharmaceut (Basel). 2010 Aug 20;3(8):2709–2732. doi: 10.3390/ph3082709
  • Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008;84(3):347–361. doi: 10.1038/sj.clpt.6100482
  • Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov;96(5):542–548. doi: 10.1038/clpt.2014.159
  • Löscher W, Klotz U, Zimprich F, et al. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009 Jan;50(1):1–23. doi: 10.1111/j.1528-1167.2008.01716.x
  • Nakajima Y, Saito Y, Shiseki K, et al. Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol. 2005 Mar;61(1):25–34. doi: 10.1007/s00228-004-0878-1
  • Shen C, Zhang B, Liu Z, et al. Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy. Seizure. 2017 Oct;51:102–106. doi: 10.1016/j.seizure.2017.07.015
  • Petrenaite V, Öhman I, Jantzen FPT, et al. Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABC1B polymorphisms on lamotrigine metabolism in Danish patients. Epilepsy Res. 2022 May;182:106897. doi: 10.1016/j.eplepsyres.2022.106897
  • Yang H, Yang L, Zhong X, et al. Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes. Eur J Pharm Sci. 2022 Oct 1;177:106258. doi: 10.1016/j.ejps.2022.106258
  • Beers JL, Fu D, Jackson KD. Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol. Drug Metab Dispos. 2021 Oct;49(10):882–891. doi: 10.1124/dmd.120.000350
  • Dean L. Lacosamide therapy and CYP2C19 genotype. In: Pratt V, Scott S Pirmohamed M, et al. Eds. Medical genetics summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012 [2018 Apr 18]. https://www.ncbi.nlm.nih.gov/books/NBK493589
  • Ahn SJ, Oh J, Kim DY, et al. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy. Epilepsia. 2022 Nov;63(11):2958–2969. doi: 10.1111/epi.17399
  • Ohkubo S, Akamine Y, Ohkubo T, et al. Quantification of the plasma concentrations of perampanel using high-performance liquid chromatography and effects of the CYP3A4*1G polymorphism in Japanese patients. J Chromatogr Sci. 2020 Oct 26;58(10):915–921. doi: 10.1093/chromsci/bmaa060
  • Wang H, Wang J, Lin B, et al. Effect of age, comedications, and CYP3A4/5 polymorphisms on perampanel exposure in Chinese pediatric patients with epilepsy. J Clin Pharmacol. 2024 Feb 21;64(6):737–743. doi: 10.1002/jcph.2415
  • Jogamoto T, Yamamoto Y, Fukuda M, et al. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res. 2017 Feb;130:7–12. doi: 10.1016/j.eplepsyres.2016.12.014

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.